A study by researchers from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have identified distinct immune “signatures” in patients who develop adverse events while taking immunotherapy for cancer. This may help oncologists identify patients at serious risk for immunotherapy-related side effects.
